S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Salarius Pharmaceuticals Stock Forecast, Price & News

-0.01 (-1.43%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
215,407 shs
Average Volume
1.70 million shs
Market Capitalization
$31.19 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Salarius Pharmaceuticals logo

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.


What Wall Street expects from Salarius Pharmaceuticals's earnings
November 5, 2021 |  markets.businessinsider.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Announces Earnings Results
November 5, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$5.23 million
Book Value
$0.94 per share


Net Income
$-7.35 million
Net Margins
Pretax Margin




Free Float
Market Cap
$31.19 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.65 out of 5 stars

Medical Sector

976th out of 1,391 stocks

Pharmaceutical Preparations Industry

460th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Salarius Pharmaceuticals (NASDAQ:SLRX) Frequently Asked Questions

Is Salarius Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Salarius Pharmaceuticals stock.
View analyst ratings for Salarius Pharmaceuticals
or view top-rated stocks.

How has Salarius Pharmaceuticals' stock price been impacted by Coronavirus?

Salarius Pharmaceuticals' stock was trading at $0.7201 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SLRX stock has decreased by 4.2% and is now trading at $0.69.
View which stocks have been most impacted by COVID-19

Are investors shorting Salarius Pharmaceuticals?

Salarius Pharmaceuticals saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 978,900 shares, a decline of 24.1% from the September 30th total of 1,290,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 6.7% of the shares of the stock are sold short.
View Salarius Pharmaceuticals' Short Interest

When is Salarius Pharmaceuticals' next earnings date?

Salarius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Salarius Pharmaceuticals

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Thursday, November, 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. Salarius Pharmaceuticals had a negative net margin of 187.50% and a negative trailing twelve-month return on equity of 27.16%. During the same period in the previous year, the business posted ($0.10) earnings per share.
View Salarius Pharmaceuticals' earnings history

What price target have analysts set for SLRX?

1 analysts have issued 12 month target prices for Salarius Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Salarius Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 624.6% from the stock's current price.
View analysts' price targets for Salarius Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Salarius Pharmaceuticals' key executives?

Salarius Pharmaceuticals' management team includes the following people:
  • David J. Arthur, President, Chief Executive Officer & Director
  • Mark J. Rosenblum, Chief Financial Officer & Executive Vice President
  • Bruce J. McCreedy, Director & Chief Scientific Officer
  • Nadeem Q. Mirza, Senior Vice President-Clinical Development

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

What is Salarius Pharmaceuticals' stock symbol?

Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLRX."

Who are Salarius Pharmaceuticals' major shareholders?

Salarius Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (1.68%), Geode Capital Management LLC (0.79%), BlackRock Inc. (0.26%), Two Sigma Advisers LP (0.25%), Millennium Management LLC (0.13%) and HighTower Advisors LLC (0.06%). Company insiders that own Salarius Pharmaceuticals stock include Arnold C Hanish, David J Arthur, Mark J Rosenblum, Scott Jordan and William K Mcvicar.
View institutional ownership trends for Salarius Pharmaceuticals

Which institutional investors are selling Salarius Pharmaceuticals stock?

SLRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Salarius Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Salarius Pharmaceuticals stock?

SLRX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Advisers LP, Geode Capital Management LLC, HighTower Advisors LLC, and Millennium Management LLC. Company insiders that have bought Salarius Pharmaceuticals stock in the last two years include Arnold C Hanish, David J Arthur, Mark J Rosenblum, Scott Jordan, and William K Mcvicar.
View insider buying and selling activity for Salarius Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Salarius Pharmaceuticals' stock price today?

One share of SLRX stock can currently be purchased for approximately $0.69.

How much money does Salarius Pharmaceuticals make?

Salarius Pharmaceuticals has a market capitalization of $31.19 million and generates $5.23 million in revenue each year. The company earns $-7.35 million in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Salarius Pharmaceuticals have?

Salarius Pharmaceuticals employs 8 workers across the globe.

What is Salarius Pharmaceuticals' official website?

The official website for Salarius Pharmaceuticals is www.salariuspharma.com.

Where are Salarius Pharmaceuticals' headquarters?

Salarius Pharmaceuticals is headquartered at 2450 Holcombe Blvd. Suite X, Houston TX, 77021.

How can I contact Salarius Pharmaceuticals?

Salarius Pharmaceuticals' mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The company can be reached via phone at (832) 834-6992 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.